Unknown

Dataset Information

0

State of the art biological therapies in pancreatic cancer.


ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with a five-year survival rate of approximately 5%. Several target agents have been tested in PDAC, but almost all have failed to demonstrate efficacy in late phase clinical trials, despite the better understanding of PDAC molecular biology generated by large cancer sequencing initiatives in the past decade. Eroltinib (a small-molecule tyrosine-kinase inhibitor of epidermal growth factor receptor) plus gemcitabine is the only schedule with a biological agent approved for advanced pancreatic cancer, but it has resulted in a very modest survival benefit in unselected patients. In our work, we report a summary of the main clinical trials (closed and ongoing) that refer to biological therapy evaluation in pancreatic cancer treatment.

SUBMITTER: Di Marco M 

PROVIDER: S-EPMC4714146 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5440286 | BioStudies
2015-01-01 | S-EPMC4502164 | BioStudies
1000-01-01 | S-EPMC3795429 | BioStudies
2019-01-01 | S-EPMC6775620 | BioStudies
2018-01-01 | S-EPMC5922405 | BioStudies
2019-01-01 | S-EPMC6408295 | BioStudies
2019-01-01 | S-EPMC6895788 | BioStudies
2019-01-01 | S-EPMC6398265 | BioStudies
2017-01-01 | S-EPMC5922269 | BioStudies
2020-01-01 | S-EPMC7216436 | BioStudies